Opdivo and Yervoy combo uptake in oncology at risk, says analyst
US pharma major Bristol Myers Squibb’s (NYSE: BMY) blockbuster combination of Opdivo (nivolumab) and Yervoy (ipilimumab) is facing increasing scrutiny in various oncology indications as to whether the financial burden and clinical toxicity added by Yervoy is worth it.
According to data and analytics company GlobalData, clinical trials with Opdivo monotherapy outnumber the trials with Opdivo and Yervoy combination.
GlobalData has identified that, out of 782 ongoing clinical trials in oncology that have listed Opdivo, Yervoy, or the combination as a primary intervention, Opdivo monotherapy represents the majority. Specifically, 61% of trials include Opdivo monotherapy, 31% of trials the combination, and only 8% include Yervoy monotherapy. Interestingly, only 20% of these trials are industry-sponsored.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Biotechnology
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze